Presenilin in Neurodegeneration: Role of Akt/ERK Pathways
About the Research Project
Program
Award Type
Standard
Award Amount
$297,819
Active Dates
April 01, 2005 - June 30, 2007
Grant ID
A2005039
Summary
Inherited mutations in two similar genes, presenilin 1 (PS1) and presenilin 2 (PS2), cause the most aggressive forms of AD with disease onset between 30 to 60 years of age. It is widely believed that these genes cause AD by accelerating amyloid plaque deposition in the brain. Growing evidence has found that presenilin dysfunctions may also drive tangle pathology independent of the effects from amyloid plaques. This finding is significant, because many therapeutic agents currently under development are designed to reduce amyloid plaques by inhibiting the functions of both PS1 and PS2. These agents may end up inadvertently promoting nerve damage and tangle formation instead. It is important to understand whether mutations in PS1 or PS2 can influence nerve damage and tangle formation independent of the effects associated with amyloid plaques. Experimental data has indicated that 2 molecular pathways (Akt and ERK) important for nerve cell survival are severely compromised in cells lacking both PS1 and PS2. Dr. Kang plans on testing whether delivery of activated Akt or ERK genes can prevent brain damage.
Related Grants
Alzheimer's Disease Research
"Cognition in a Dish" to Develop New Alzheimer’s Therapies
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Matthias Hebisch, PhD
Current Organization
Massachusetts General Hospital
"Cognition in a Dish" to Develop New Alzheimer’s Therapies
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Matthias Hebisch, PhD
Current Organization
Massachusetts General Hospital
Alzheimer's Disease Research
Why Alzheimer’s Disease Targets Some Cells First: A Clue in the Anterior Hypothalamus
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Gowoon Son, PhD
Current Organization
Mayo Clinic Jacksonville
Why Alzheimer’s Disease Targets Some Cells First: A Clue in the Anterior Hypothalamus
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Gowoon Son, PhD
Current Organization
Mayo Clinic Jacksonville
Alzheimer's Disease Research
Probing the Novel Roles of Neuromodulators in Alzheimer’s Disease
Active Dates
July 01, 2026 - June 30, 2029
Principal Investigator
Fikri Birey, PhD
Current Organization
Emory University
Probing the Novel Roles of Neuromodulators in Alzheimer’s Disease
Active Dates
July 01, 2026 - June 30, 2029
Principal Investigator
Fikri Birey, PhD
Current Organization
Emory University